A major secretory protein of the human epididymis that is taken up by maturing spermatozoa is homologous to the leukocyte antigen CD52. The epididymis was shown to be the sole source of CD52 in seminal fluid, since CD52 could be detected in seminal plasma from sperm-containing ejaculates and not in ejaculates of vasectomized patients by Western blot analysis. The glycoprotein is not expressed in the testes. A fluorescence immunobinding assay was developed to quantify the amount of epididymal secretion of CD52 in the seminal plasma of various groups of fertile and infertile patients. Donor spermatozoa bearing CD52 were used as binding site tracers for free anti-CD52 antibody remaining after it had adsorbed CD52 from the seminal plasma to be assayed. The level of subsequent antibody binding to spermatozoa was measured by flow cytometry and the extent of binding inhibition was compared to a reference pool of seminal plasma to provide relative amounts of CD52 in test seminal plasma. There were no correlations between seminal plasma CD52 concentration and any semen parameter tested, including sperm concentration, percentage motility, normal sperm morphology or the concentration of seminal neutral α-glucosidase, fructose and zinc. There was a slight tendency towards an inverse relationship with the amount of CD52 on spermatozoa, but this was not significant. No differences were found among groups of patients classified by their semen parameters or fertility status. These findings indicate that the epididymal specific supply of CD52 is not a limiting factor for CD52 uptake onto spermatozoa.
Introduction
It is well established in mammals that the natural fertilizing capacity of spermatozoa is acquired upon maturation in the epididymis, an organ which is also crucial for sperm storage (see Amann et al., 1993; Cooper, 1995) . However, the controversy of the role of the epididymis in men is still unresolved (Cooper, 1990 (Cooper, , 1993 Bedford, 1994) and is partly due to the paucity of evidence for well defined functions of human epididymal secretions and their interaction with spermatozoa. Changes in maturing human epididymal spermatozoa include their increasing potential, once released from the tract, to progress forwards (Yeung et al., 1993) , to bind to the zona (Moore et al., 1992) , to respond to acrosome reaction inducers (Yeung et al., 1997a) and to fuse with zona-free eggs (Moore et al., 1983) . Some of these maturational events (zona binding, egg fusion) are directly or indirectly dependent upon epididymal secretions (Boué et al., 1995; 1996; Lefevre et al., 1997) , which bind to or otherwise interact with sperm membranes. The stimulation in vitro of immature epididymal sperm motility by certain phospholipids (Haidl et al., 1994) also suggests that membrane composition is important for this sperm function. It is now known that there are both chemical and physical changes to membranes of maturing human spermatozoa (Haidl and Opper, 1997) and epididymal secretions may be involved in these modifications. In a previous study a relationship between the epididymal secretion HE5 (CD52) and ejaculated sperm motility was demonstrated by a decreased sperm surface expression of the glycoprotein in samples of low motility (Yeung et al., 1997b) .
HE5 has been identified as a major transcript of an epididymal specific gene with a cDNA sequence homologous to CD52 (see Kirchhoff, 1996) . CD52 is found on lymphocytes and monocytes as a glycosylphosphatidylinositol (GPI)-anchored glycoprotein with only 12 amino acids and heavy glycosylation at an asparagine site (Hale et al., 1990; Xia et al., 1993) . The physiological role of the molecule is unknown despite many clinical applications of the use of its antibody in lymphocyte depletion such as in the treatment of lymphoma, rheumatoid arthritis, bone marrow and organ transplantations (see Ettenger and Yadin, 1995) . The mRNA transcript of CD52 has been localized in the corpus and cauda epididymidis and the protein is absent from the testis but present at high levels in the epididymal epithelium and lumen (Hale et al., 1993) , as revealed by the monoclonal antibodies CAMPATH-1 developed for therapeutic use (Hale et al., 1988) . CD52 is secreted and accumulates in the epididymis, as indicated by its detection in Western blots of luminal fluid from the cauda in higher amounts than that from corpus region (Yeung et al., 1997c) . It is absent from immature spermatozoa in the efferent ducts but is taken up progressively as they move into the epididymis proper, reflected by the stepwise increase in the percentage of spermatozoa stained by CAMPATH-1G, as well as in the staining intensity, along the length of the epididymal tubule (Yeung et al., 1997c) .
The physiological significance of the secretion by the epididymis and the coating on spermatozoa in high amounts of this lymphocyte antigen is unclear. The profile of increase in its mRNA levels along the length of the epididymal tubule as assessed by in-situ hybridization, particularly in the proximal half of the corpus reaching a plateau in the distal corpus , parallels the pattern of maturation of sperm motility and kinematics (Yeung et al., 1993) . It is uncertain if these are merely concurrent events along the reproductive tract, or whether there is a direct involvement of CD52 in the development of sperm motility, since incubation of ejaculated spermatozoa with CD52 antibody reduces some kinematic parameters slightly (Yeung et al., 1997b) .
The aim of the present study was to investigate if semen quality is correlated to the amount of secreted CD52 present in the seminal plasma, in an attempt to reveal any potential role of this glycoprotein in fertility. However, currently there is no available assay for CD52. ELISA cannot be established since no purified or synthetic CD52 exists, despite its known amino acid sequence, because it has a high carbohydrate content of unknown composition. Thus an assay was developed based on the observations of Hale et al. (1993) that when seminal plasma is present during the incubation of washed spermatozoa with the anti-CD52 antibody CAMPATH-1G, the CD52 molecules in the seminal plasma compete with spermbound CD52 for the antibodies, resulting in a decrease in antibody-binding to the sperm surface. The extent of this inhibition should vary according to the amount of CD52 in the seminal plasma. As binding of the antibody to live spermatozoa can be quantified by dual-parameter flow cytometry (Yeung et al., 1997b,c) , in this study a binding assay was established to quantify the concentration of CD52 in seminal plasma from patients by comparing the inhibition by the seminal plasma of CAMPATH-1G staining of washed donor spermatozoa with a reference pool of seminal plasma.
Materials and methods

Patients and seminal plasma samples
The core study included ejaculates provided by 78 consecutive normal and infertile men attending the clinic of the Institute of Reproductive Medicine, Münster, whose semen samples were investigated by full routine semen analysis including chemical tests for accessory gland markers, performed according to the manual of the World Health Organisation (1992). Azoospermic samples and those with a sperm concentration Ͻ 3ϫ10 6 /ml were not included because investigation of correlations with sperm parameters were intended.
To investigate the source of CD52 in seminal plasma, additional ejaculate samples from three vasectomized patients were used, which were confirmed to contain no spermatozoa and no or low neutral α-glucosidase activities (clinical epididymal marker) by routine semen analysis. An aliquot of each ejaculate after routine clinical analysis was centrifuged at 2000 g for 10 min and the seminal plasma stored at -20°C until use.
Identification of CD52 in seminal plasma by Western blotting
Known volumes of sperm-free seminal plasma were extracted using methanol/chloroform and aliquots of the processed samples equivalent to 15 µl of the original seminal plasma were analysed as previously described (Yeung et al., 1997c) . In brief, protein bands separated by 15% gel electrophoresis were blotted onto PVDF membranes and incubated with CAMPATH-1G followed by peroxidase-conjugated secondary antibody visualized by chemiluminescence.
Preparation of the reference seminal plasma pool and donor spermatozoa
The seminal plasma reference was prepared by pooling from normozoospermic ejaculates, which were first centrifuged at 2000 g for 5 min at room temperature to remove spermatozoa and the supernatant again at 5000 g at 4°C for 10 min to remove any remaining cells. The pool was vortexed, divided into aliquots and stored at -20°C. Donor spermatozoa providing binding sites for the assay were prepared by washing 1-2 ml normozoospermic ejaculate through 3 ml 35% (v/v) and 3 ml 70% (v/v) Percoll in Ham's F-10 medium. The sperm pellet was washed again in Ham's medium containing 4 mg/ml bovine serum albumin (BSA), resuspended to 25ϫ10 6 /ml and kept in an incubator in 5% (v/v) CO 2 at 37°C until use. One donor sperm sample was used in each assay.
Competitive binding assay and flow cytometric analysis
The parameter measured in the assay using flow cytometry was CD52 antibody staining intensity of donor spermatozoa after competitive inhibition of antibody binding by test seminal plasma CD52. Calculation of CD52 concentrations in seminal plasma was done separately for each assay, with reference to the common pool of seminal plasma used as internal standard for all assays as described below. Seminal plasma samples stored at -20°C were thawed and centrifuged at 5000 g for 5 min at 4°C before the assay. The reference sample was diluted, using phosphate buffered saline (PBS, Gibco, Eggenstein, Germany) containing 2 mM protease inhibitor (Pefabloc ® ; Merck, Darmstadt, Germany), in a series of 1:4, 8, 16 and 32 and the patients' samples diluted to 1:8 and 1:16. To 50 µl of each diluted sample, 5 µl of CAMPATH-1G (monoclonal rat IgG against CD52, a gift from Prof. Geoffrey Hale) was added to a dilution of 1:200 and kept at room temperature for 5 min. The dilution factors used for the seminal plasma and the antibody were determined during the establishment and validation of the assay to give around 20-80% inhibition of the maximal binding to washed sperm samples. After 5 min equilibration, 50 µl donor spermatozoa was added to each diluted seminal plasma as a source of detectable antibody-binding sites (to be measured as staining intensity), and incubated at room temperature for 20 min before washing twice with PBS containing 4 mg/ml BSA. Staining with FITC-conjugated secondary antibody and with propidium iodide (5 µg/ml for 5 min) for cell viability and the analysis of the staining intensity of viable spermatozoa by measuring about 5000 cells from each sample using a flow cytometer (Coulter Epics XL; Kiefeld, Germany) were performed as previously described (Yeung et al., 1997b) . Results were obtained, as described below, from the mean staining intensity of the viable donor spermatozoa. For each assay, a reference (internal standard) curve was constructed by plotting the staining intensity of the donor spermatozoa against the dilutions of the reference seminal plasma pool (Figure 1) , which would indicate the extent and the linear range of the inhibition of donor sperm CD52 staining by the reference sample. The concentration of CD52 in each patient's seminal plasma sample was expressed as the equivalent percentage of the reference pool giving the same level of staining inhibition in the same assay. Mean variation between Figure 1 . A representative assay of CD52 in the seminal plasma of eight patients (each indicated by a line) where the amounts of binding of the monoclonal antibody to donor spermatozoa in the presence of two dilutions (usually by ϫ8 and ϫ16, x-axis) of each seminal plasma were detected and quantified as mean fluorescence intensity (staining intensity, y-axis) using flow cytometry. An internal standard curve is obtained from four dilutions of the reference pool of seminal plasma. The relative concentrations of CD52 in the samples were calculated from the dilutions of the reference pool giving the same staining intensity.
values calculated from the two dilutions of each test sample was 20%, and the averaged value was used as the result. Assay results were rejected when linearity of the reference curve was not achieved in the plot of staining intensity against dilution. Samples failing to show parallelism with the reference curve (usually because of too low a content of CD52) were reanalysed in another assay using lower dilutions. An example of an assay is shown in Figure 1 . Mean intraassay coefficient of variation calculated from repeated measurements of the reference pool was 8.6%; mean inter-assay coefficient of variation in measuring the same patients' samples was 19.5%.
Measurement of CD52 on ejaculated spermatozoa
For each ejaculate, an aliquot was washed twice and spermatozoa were resuspended to 10-40ϫ10 6 /ml and incubated with the antibody CAMPATH-1G, or rat serum IgG to control for non-specific binding, followed by staining with the FITC-conjugated rabbit anti-rat IgG. After addition of propidium iodide (PI) as vital stain, about 5000 sperm cells gated by forward and side scattered signals were analysed for FITC and PI fluorescence. The percentage of PI negative spermatozoa showing FITC staining above the control level, and the mean fluorescence intensity for each sample, were assessed.
Statistics
Data were analysed using one-way analysis of variance and differences between groups tested using the Student-Neuwman-Keuls method (statistic software: SigmaStat ® ; Jandel Corporation, Erkrath, Germany). 
Results
Identification and source of CD52 in seminal plasma
CD52 in seminal plasma from four normozoospermic ejaculates was identified by Western blotting as two or more protein bands with molecular sizes between 20-24 kDa (Figure 2) . The total intensity of immunostaining from the same volume of seminal plasma, as well as which band was dominant, varied among patients. This variability was also reflected by the fluorescence immunoassay results given below (see scattered x-axis values in Figure 3) . No cross-reacting protein bands with similar electrophoretic mobility were detected in the seminal plasma of the three vasectomized patients ( Figure  2, lanes F-H) .
Quantification of CD52 in seminal plasma and correlation with CD52 staining characteristics of spermatozoa
When measured against a reference pool, the concentration of CD52 immuno-activity in the seminal plasma varied among patients, with the upper quartile value being 2.4 times that of the lower quartile. There was no clear correlation of these concentrations with the percentages of viable spermatozoa from the ejaculate showing positive CD52 staining ( Figure  3a ), whereas correlation with sperm CD52 staining intensity suggested an inverse trend of higher sperm CD52 being associated with a lower concentration in seminal plasma although the linear regression just failed to reach statistical significance (P ϭ 0.056, Figure 3b ).
Lack of correlation between seminal plasma CD52 and semen parameters
There were no correlations between seminal plasma CD52 concentrations and any semen parameter tested, including sperm concentration, percentage motility, normal sperm morphology, or the concentrations of seminal neutral α-glucosidase, fructose and zinc.
Seminal plasma CD52 in patients classified by spermiograms or fertility status
No differences could be detected among the groups of patients classified as normozoospermic, teratozoospermic as the sole semen abnormality, oligozoospermic, or asthenozoospermic (Table I) . Similar concentrations of CD52 were also found in seminal plasma from ejaculates where the spermatozoa were tested positive or negative for IgG (70.4 Ϯ 10.3 and 65.7 Ϯ 5.0% reference pool; n ϭ 19 and 59 respectively) or for IgA (73.8 Ϯ 14.7 and 65.9 Ϯ 4.8% reference, n ϭ 10 and 68 respectively), or when the ejaculates contained leukocytes above or below the detection limit of 0.5ϫ10 6 /ml (76.8 Ϯ 8.9 and 62.7 Ϯ 5.2% reference, n ϭ 23 and 55 respectively). Neither were there differences among them when grouped 
Discussion
The absence of CD52 from the seminal plasma of vasectomized men agrees with a recent report (Rooney et al., 1996) and confirms the epididymis as the source of this seminal glycoprotein, since the testis does not express it . The antigen localized in the seminal vesicle epithelium in an earlier study (Hale et al., 1993) is therefore unlikely to be secreted. In the present study, an assay was established to compare seminal plasma CD52 concentration against a reference pool using the monoclonal antibody CAMPATH-1G and flow cytometry. Washed human donor spermatozoa were used as tracers to provide the antigen binding sites for the antibody which could be quantified. Prior incubation of the antibody with dilutions of seminal plasma reduced the amount of antibody available for subsequent binding to the donor spermatozoa, and the extent of this reduction should reflect the amount of CD52 in the tested seminal plasma. The spermbound antibodies were revealed using indirect immunofluorescence labelling and quantified by flow cytometric analysis, and the extent of inhibition compared against the reference pool of seminal plasma. There were differences of several fold in the concentrations of CD52 in seminal plasma among the 78 subjects investigated. However, no differences were found among groups of patients classified by their semen parameters or fertility status. When all patients were taken together, the variations in CD52 concentrations were independent of any parameter of sperm quality or quantity, or biochemical markers for accessory gland secretions including epididymal neutral α-glucosidase. Whereas the activity of neutral α-glucosidase in seminal plasma indicates one aspect of epididymal secretory activity, and is used routinely to detect distal epididymal and vasal occlusion , the content of CD52 clearly does not, since some of the secretion is taken up by spermatozoa. Indeed the present results suggest an inverse relationship between the concentration of CD52 in seminal plasma and the amount on spermatozoa. Unfortunately, the combined amount of CD52 could not be estimated with the present methods. Nevertheless, the data indicate that the supply of CD52 was not the limiting factor for the uptake onto spermatozoa. This, and the finding that almost all mature epididymal (Yeung et al., 1997c) and ejaculated spermatozoa (Yeung et al., 1977b) are normally coated by the glycoprotein, and the fact that the gene expression is independent of androgen alone (Pera et al., 1997) , suggest a continual constitutive secretion of epididymal CD52, which is always in excess of requirement for sperm coating.
In our previous study (Yeung et al., 1977b) , there was a correlation between the quantitative measurements of CD52 on spermatozoa with sperm motility, with asthenozoospermic patients having a lower level of sperm CD52 expression in terms of the percentage of positive cells as well as the amount of the antigen bound. This suggested that this epididymal glycoprotein may be related to the development of sperm motility upon maturation. However, the CD52 concentration in the seminal plasma of these asthenozoospermic patients was not any lower than that in normozoospermic samples, suggesting that the lower amount of sperm-bound CD52 in asthenozoospermia is due to the spermatozoa rather than insufficient secretion of the glycoprotein. As there were no differences in the seminal plasma among groups of patients with different seminal parameters and different fertility status, the present study fails to provide any additional clue as to the role of CD52 in reproduction. A recent study has shown that transfected CHO cell lines expressing different levels of CD52 differ in their ability to attach to the culture stratum and in their growth when transplanted into nude mice, suggesting a role in cell adhesion or protection in the host environment (Hale et al., 1996) . The persistence of CD52 on both head and tail of viable ejaculated spermatozoa after overnight incubation for capacitation, which leads to an increase in antibody staining intensity (Yeung et al., 1977c) , is compatible with the possibility of a similar role in the female tract. At present, only three human epididymal secretions have a postulated function in fertilization, FLB1 (Boué et al., 1995) and SOB2 (Lefevre et al., 1997) , which are involved in oocyte fusion, and P34H which is involved in zona binding (Boué et al., 1996) . The role of the major epididymal secretory protein CD52 remains unclear.
